Xu Shao , Muqiong Li , Chaoren Yan , Chao Wang , Xin Wang , Ping Guan , Xiaoling Hu , Li Fan
{"title":"Photocatalytic, photothermal, and blood-brain barrier-permeable carbon nanodots: A potent multifunctional scavenger for β-amyloid plaque","authors":"Xu Shao , Muqiong Li , Chaoren Yan , Chao Wang , Xin Wang , Ping Guan , Xiaoling Hu , Li Fan","doi":"10.1016/j.colsurfb.2024.114380","DOIUrl":null,"url":null,"abstract":"<div><div>Alzheimer’s disease (AD) is associated with amyloid production and buildup in the brain, leading to neurodegeneration. In this study, we used a solvent-thermal technique to produce light-sensitive carbon nanodots (L-CNDs). L-CNDs exhibit outstanding photocatalytic properties, producing singlet oxygen (<sup>1</sup>O<sub>2</sub>) under 630 nm irradiation. L-CNDs have a high photothermal conversion efficiency of 68.25 % under 808 nm irradiation, allowing for localized heating and regulation of A<em>β</em> aggregation. L-CNDs bind A<em>β</em> through hydrophobic interaction and π-π stacking. L-CNDs inhibit A<em>β</em> aggregation with efficiencies of 61.08 %, 75.09 %, and 91.72 % at 10 μg·mL<sup>−1</sup> in photothermal therapy (PTT), photodynamic therapy (PDT), and PTT/PDT synergistic therapy, respectively. L-CNDs efficiently suppress A<em>β</em> misfolding, inhibit fibrillation, and promote disaggregation of mature fibrils. L-CNDs mitigate A<em>β</em>-induced cytotoxicity in PC12 and HT22 cells. Interestingly, the data showed that 84.6 % of the L-CNDs could penetrate bEnd.3 cells after 8 h of treatment, demonstrating that they have the capacity to cross the blood-brain barrier (BBB) because of their small size. <em>In vitro</em> investigations have shown that L-CNDs can pass through the BBB. Collectively, our findings reveal a unique technique for treating amyloid disorders using carbon nanodots with significant potential for future studies in this area.</div></div>","PeriodicalId":279,"journal":{"name":"Colloids and Surfaces B: Biointerfaces","volume":"246 ","pages":"Article 114380"},"PeriodicalIF":5.4000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloids and Surfaces B: Biointerfaces","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0927776524006398","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0
Abstract
Alzheimer’s disease (AD) is associated with amyloid production and buildup in the brain, leading to neurodegeneration. In this study, we used a solvent-thermal technique to produce light-sensitive carbon nanodots (L-CNDs). L-CNDs exhibit outstanding photocatalytic properties, producing singlet oxygen (1O2) under 630 nm irradiation. L-CNDs have a high photothermal conversion efficiency of 68.25 % under 808 nm irradiation, allowing for localized heating and regulation of Aβ aggregation. L-CNDs bind Aβ through hydrophobic interaction and π-π stacking. L-CNDs inhibit Aβ aggregation with efficiencies of 61.08 %, 75.09 %, and 91.72 % at 10 μg·mL−1 in photothermal therapy (PTT), photodynamic therapy (PDT), and PTT/PDT synergistic therapy, respectively. L-CNDs efficiently suppress Aβ misfolding, inhibit fibrillation, and promote disaggregation of mature fibrils. L-CNDs mitigate Aβ-induced cytotoxicity in PC12 and HT22 cells. Interestingly, the data showed that 84.6 % of the L-CNDs could penetrate bEnd.3 cells after 8 h of treatment, demonstrating that they have the capacity to cross the blood-brain barrier (BBB) because of their small size. In vitro investigations have shown that L-CNDs can pass through the BBB. Collectively, our findings reveal a unique technique for treating amyloid disorders using carbon nanodots with significant potential for future studies in this area.
期刊介绍:
Colloids and Surfaces B: Biointerfaces is an international journal devoted to fundamental and applied research on colloid and interfacial phenomena in relation to systems of biological origin, having particular relevance to the medical, pharmaceutical, biotechnological, food and cosmetic fields.
Submissions that: (1) deal solely with biological phenomena and do not describe the physico-chemical or colloid-chemical background and/or mechanism of the phenomena, and (2) deal solely with colloid/interfacial phenomena and do not have appropriate biological content or relevance, are outside the scope of the journal and will not be considered for publication.
The journal publishes regular research papers, reviews, short communications and invited perspective articles, called BioInterface Perspectives. The BioInterface Perspective provide researchers the opportunity to review their own work, as well as provide insight into the work of others that inspired and influenced the author. Regular articles should have a maximum total length of 6,000 words. In addition, a (combined) maximum of 8 normal-sized figures and/or tables is allowed (so for instance 3 tables and 5 figures). For multiple-panel figures each set of two panels equates to one figure. Short communications should not exceed half of the above. It is required to give on the article cover page a short statistical summary of the article listing the total number of words and tables/figures.